The brokerage currently has a $6.00 price target on the biotechnology company’s stock. BCRX has been the subject of a number of other reports.
The brokerage currently has a $6.00 price target on the biotechnology company’s stock. BCRX has been the subject of a number of other reports.
0 Comments